A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Trial Profile

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CREDENCE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 17 Aug 2018 This trial has been completed in France, according to European Clinical Trials Database.
    • 18 Jul 2018 According to a Mundipharma International media release, this trial has been stopped early, based on a decision from the Independent Data Monitoring Committee (IDMC). The recommendation is based on demonstration of efficacy as the trial achieved pre-specified criteria for the primary composite end points.
    • 16 Jul 2018 According Janssen Pharmaceuticals media release, company is looking forward to presenting the full data from the CREDENCE trial at an upcoming medical meeting and with health authorities in the near future.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top